MDMA therapy is facing an imminent FDA decision. Here’s what you need to know
A decades-long campaign to legalize MDMA as a mainstream medical treatment will reach a climax as soon as Friday, with the Food and Drug Administration poised to decide whether the psychedelic should be approved as a treatment for post-traumatic stress disorder in conjunction with psychotherapy.
The regulators face an Aug. 11 deadline to decide whether to sign off on the drug or reject it. The agency could also postpone its decision if it needs more time to review data and investigate claims of irregularities in clinical trials run by Lykos Therapeutics.
